IMMUNO-COV SCIENTIFIC DOCUMENTS, PRESENTATIONS & FAQ

DEVELOPMENT AND VALIDATION

Development and validation of IMMUNO-COV: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2

Download

SENSITIVITY SPECIFICITY

IMMUNO-COV™ Assay Sensitivity and Specificity: Based on assay validation and verification data obtained in April and May, 2020

Download

IMMUNO-COV PRESENTATION

Genome Writers Guild 2020 : Development and Validation of a High-throughput Clinical Test to Detect Anti-SARS-CoV-2 Neutralizing Antibodies

Download

ASGCT IMMUNO-COV PRESENTATION

The American Society of Gene & Cell Therapy COVID-19 Symposium presentation of the development and validation of IMMUNO-COV: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2

FAQ

In tests so far, IMMUNO-COV has shown 100% agreement with people who tested positive for COVID-19 antibodies by ELISA (another type of serology test), and zero false positives have been detected in people known to be negative for COVID-19. There is a small chance that IMMUNO-COV could give a false result.

We are still studying if neutralizing antibodies detected by IMMUNO-COV can protect from new infection with the COVID-19 virus. Updates about this will be provided as researchers uncover new information.

We do not know yet whether having COVID-19 immunity will prevent you from infecting others. We suggest that you follow the U.S. Government guidelines on how and when you can return to work or school. Your healthcare provider can assist you with the guidelines.

We do not know yet whether having COVID-19 immunity will prevent you from infecting others. We suggest that you follow the U.S. government guidelines on how and when you can visit others. Your healthcare provider can help you with the guidelines.

We do not yet know how long COVID-19 immunity lasts. We know that people who are infected with other coronaviruses, such as MERS virus or SARS virus, are unlikely to be re-infected soon after recovering. However, we do not know whether we will see similar immunity against the COVID-19 virus.

IMMUNO-COV has been developed by Vyriad, a biotechnology company based in Rochester, Minnesota, with support from Imanis Life Sciences (Rochester, Minnesota) and in collaboration with Regeneron Pharmaceuticals (Tarrytown, New York) and Mayo Clinic (Rochester, Minnesota).

If your primary interest is for research and institutional entities please submit a request via the inquiry tabs.
At this time we are not accepting individual samples from physicians. Please sign up for updates and we will advise you when available.

©2020 Imanis Life Sciences. All rights reserved.

Log in with your credentials

Forgot your details?